Año 2025 / Volumen 117 / Número 4
Original
Impact of ustekinumab exposure on clinical outcomes during induction in inflammatory bowel disease

205-212

DOI: 10.17235/reed.2024.10521/2024

Carles Iniesta-Navalón, Manuel Ríos-Saorín, Lorena Rentero-Redondo, Isabel Nicolás-de Prado, Rosa Gómez-Espín, Elena Urbieta-Sanz,

Resumen
Background: understanding the relationship between ustekinumab (UST) exposure and clinical outcomes in inflammatory bowel disease (IBD) induction is crucial. However, evidence remains limited, highlighting the need to comprehend UST’s pharmacokinetic variability for tailored treatments. Aims: this study aimed to investigate the association between UST exposure during the induction phase and clinical outcomes and identifying factors associated with UST exposure during this period. Methods: a retrospective observational study was conducted on a cohort of consecutive IBD patients. The primary endpoint was to assess the association between UST exposure at week 8 and both clinical and biochemical remission at week 26, as well as the absence of disease flare-ups during the initial six months of treatment. The secondary endpoint was to investigate the relationship between baseline characteristics and UST exposure at week 8. Results: a total of 56 IBD patients were included. Variables associated with adequate UST exposure included baseline fecal calprotectin < 500 µg/g (OR: 7.72 [95 % CI: 1.75-34.03]) and female sex (OR: 4.56 [95 % CI: 1.12-18.60]). A cut-off UST trough levels of 8.3 μg/ml yielded an area under the curve (AUC) of 0.74 (95 % CI: 0.58-0.90, p = 0.021) to predict normal fecal calprotectin levels, and 8.6 µg/ml resulted in an AUC of 0.724 (95 % CI: 0.558-0.863) to predict clinical remission. Conclusions: this study demonstrates a significant association between UST concentrations and clinical and biochemical remission in IBD patients. Results suggest that standard induction doses may not be sufficient for all patients, highlighting the importance of treatment individualization to optimize outcomes.
Resumen coloquial
This research addressed the impact of Ustekinumab exposure on patients with inflammatory bowel disease (IBD) during the first six months of treatment, also exploring pharmacokinetic variability. Significant variability in Ustekinumab levels was observed, linked to differences in clinical and biochemical remission, as well as in flare prevention. Higher Ustekinumab levels at week 8 consistently correlated with better clinical outcomes by week 26, suggesting a potential therapeutic target for optimizing Ustekinumab dosing in IBD patients. This supports the need to consider treatment individualization and monitoring Ustekinumab concentrations, as standard doses may not be suitable for all patients, especially those with higher risk profiles. These findings underline the importance of personalized care to optimize clinical outcomes in IBD.
Nuevo comentario
Comentarios
No hay comentarios para este artículo.
Artículos relacionados

Carta

Linfoma T hepatoesplénico y enfermedad inflamatoria intestinal

DOI: 10.17235/reed.2023.9472/2023

Revisión

Escenarios clínicos con tofacitinib en colitis ulcerosa

DOI: 10.17235/reed.2022.8660/2022

Carta

Apoptotic colopathy as a manifestation of Good’s syndrome

DOI: 10.17235/reed.2021.8297/2021

Original

Radon exposure and inflammatory bowel disease in a radon prone area

DOI: 10.17235/reed.2021.8239/2021

Revisión

Enfermedad inflamatoria intestinal y trasplante de órganos sólido

DOI: 10.17235/reed.2020.7361/2020

Editorial

Diet in the etiology of inflammatory bowel disease

DOI: 10.17235/reed.2018.6119/2018

Caso Clínico

Lesiones serradas en pacientes con enfermedad inflamatoria intestinal

DOI: 10.17235/reed.2019.5910/2018

Editorial

Redes sociales online y enfermedad inflamatoria intestinal

DOI: 10.17235/reed.2018.5496/2018

Carta al Editor

Hipertensión portal idiopática por tiopurinas

DOI: 10.17235/reed.2018.5256/2017

Instrucciones para citar
Iniesta-Navalón C, Ríos-Saorín M, Rentero-Redondo L, Nicolás-de Prado I, Gómez-Espín R, Urbieta-Sanz E, et all. Impact of ustekinumab exposure on clinical outcomes during induction in inflammatory bowel disease. 10521/2024


Descargar en un gestor de citas

Descargue la cita de este artículo haciendo clic en uno de los siguientes gestores de citas:

Métrica
Este artículo ha sido visitado 1592 veces.
Este artículo ha sido descargado 74 veces.

Estadísticas de Dimensions


Estadísticas de Plum Analytics

Ficha Técnica

Recibido: 06/05/2024

Aceptado: 24/11/2024

Prepublicado: 04/12/2024

Publicado: 03/04/2025

Tiempo de revisión del artículo: 197 días

Tiempo de prepublicación: 212 días

Tiempo de edición del artículo: 332 días


Compartir
Este artículo aun no tiene valoraciones.
Valoración del lector:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
La REED es el órgano oficial de la Sociedad Española de Patología Digestiva, la SociedadEspañola de Endoscopia Digestiva y la Asociación Española de Ecografía Digestiva
Política de cookies Política de Privacidad Aviso Legal © Copyright 2025 y Creative Commons. Revista Española de Enfermedades Digestivas